Blueprint Medicines (BPMC) recently released updated data from its ongoing, registration-enabling EXPLORER trial of avapritinib in patients with systemic mastocytosis (SM).  The updated data reveals a confirmed overall response rate (ORR) of 77% in advanced SM...